66 related articles for article (PubMed ID: 33594044)
1. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
Jiang J; Jiang L; Maldonato BJ; Wang Y; Holderfield M; Aronchik I; Winters IP; Salman Z; Blaj C; Menard M; Brodbeck J; Chen Z; Wei X; Rosen MJ; Gindin Y; Lee BJ; Evans JW; Chang S; Wang Z; Seamon KJ; Parsons D; Cregg J; Marquez A; Tomlinson ACA; Yano JK; Knox JE; Quintana E; Aguirre AJ; Arbour KC; Reed A; Gustafson WC; Gill AL; Koltun ES; Wildes D; Smith JAM; Wang Z; Singh M
Cancer Discov; 2024 Apr; ():OF1-OF24. PubMed ID: 38593348
[TBL] [Abstract][Full Text] [Related]
2. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain.
DeLiberty JM; Robb R; Gates CE; Bryant KL
Adv Cancer Res; 2022; 153():267-304. PubMed ID: 35101233
[TBL] [Abstract][Full Text] [Related]
3. Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile.
Brown K; Jenkins LMM; Crooks DR; Surman DR; Mazur SJ; Xu Y; Arimilli BS; Yang Y; Lane AN; Fan TW; Schrump DS; Linehan WM; Ripley RT; Appella E
Front Oncol; 2022; 12():1094210. PubMed ID: 36713582
[No Abstract] [Full Text] [Related]
4. Cancer cell membrane-coated upconversion nanoparticles/Zn
Liu X; Chu Z; Chen B; Ma Y; Xu L; Qian H; Yu Y
Mater Today Bio; 2023 Oct; 22():100765. PubMed ID: 37636984
[TBL] [Abstract][Full Text] [Related]
5. Kinetic Effects of Transferrin-Conjugated Gold Nanoparticles on the Antioxidant Glutathione-Thioredoxin Pathway.
Sebastian S; Hoffmann MK; Howard D; Young C; Washington J; Unterweger H; Alexiou C; Turnbull T; D'Andrea R; Hoffmann P; Kempson I
Antioxidants (Basel); 2023 Aug; 12(8):. PubMed ID: 37627612
[TBL] [Abstract][Full Text] [Related]
6. Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis.
Kobayashi H; Imanaka S; Shigetomi H
Oncol Lett; 2022 Mar; 23(3):80. PubMed ID: 35111249
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?
McCann C; Kerr EM
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283054
[TBL] [Abstract][Full Text] [Related]
8. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
9. Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy.
Bartolacci C; Andreani C; El-Gammal Y; Scaglioni PP
Front Mol Biosci; 2021; 8():706650. PubMed ID: 34485382
[No Abstract] [Full Text] [Related]
10. Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.
Liu M; Wang D; Luo Y; Hu L; Bi Y; Ji J; Huang H; Wang G; Zhu L; Ma J; Kim E; Luo CK; Abbruzzese JL; Li X; Yang VW; Li Z; Lu W
Cell Death Dis; 2021 Feb; 12(2):189. PubMed ID: 33594044
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of K-ras-transformed pancreatic cancer cells by targeting NAD(P)H oxidase.
Wang P; Sun YC; Lu WH; Huang P; Hu Y
Chin J Cancer; 2015 Apr; 34(4):166-76. PubMed ID: 25963558
[TBL] [Abstract][Full Text] [Related]
12. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
[TBL] [Abstract][Full Text] [Related]
14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
